Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Sign Up to like & getrecommendations! Published in 2022 at "MMWR. Morbidity and mortality weekly report"
DOI: 10.15585/mmwr.mm7108a1
Abstract: On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT),… read more here.
Keywords: tuberculosis; month; regimen treatment; susceptible pulmonary ... See more keywords